REUTERS: The U.S. Centers for Medicare and Medicaid Services will slightly increase coverage for expensive CAR-T cell therapies administered at certain large hospitals, and is considering other ways to pay more for the cancer treatments, the agency said on Tuesday.
Gilead said it was still reviewing the CMS proposal, but was encouraged by comments regarding payment. Novartis did not immediately respond to a request for comment.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: